Loxo Oncology Inc (Nasdaq:LOXO)
February 13th, 2019
Amidst rising markets Loxo Oncology Inc closed the day up $0.02 Wednesday, a 0.01% increase, closing at $234.73. Furthermore it hit a new 52 week high of $234.93. The stock continues to trade well at 154.26% of its 52 week low of $92.32. While it is positive news the stock ended higher, the trading volumes were only 16.00% of normal which could be an indication of investor uncertainty. It’s expected that Loxo Oncology Inc will report earnings within the next couple of weeks.
Results from 9 analysts suggest that Loxo Oncology Inc could drop somewhat (-4.13%).
The market sectors were mixed Wednesday with a majority of the sectors trending up. Energy saw the biggest increase of the day (1.29%), while Utilities saw the biggest drop (-0.31%). Industrials has seen the biggest year-to-date gain at 15.68%.
Energy saw the biggest turnaround from its 5-day performance of -1.99%, as it went up 1.29%. Utilities saw a turn around from its 5-day performance of 1.76% trading down -0.31%.
- Energy went up with a 1.29% change.
- Industrials went up with a 0.63% change.
- Consumer Discretionary went up with a 0.62% change.
- Real Estate went up with a 0.58% change.
- Consumer Staples went up with a 0.25% change.
- Healthcare went up with a 0.25% change.
- Financials went up with a 0.20% change.
- Information Technology went up with a 0.14% change.
- Materials went up with a 0.10% change.
- Communication Services went down with a -0.10% change.
- Utilities went down with a -0.31% change.
Loxo Oncology Inc Info
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.